Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival

Cancer Biology and Therapy

Volumn 7, Issue 9, 2008, Pages 1441-1449

  Barnhart, Bryan C ^a   Lam, Jennifer C ^a,b   Young, Regina M ^a   Houghton, Peter J ^c   Keith, Brian ^a,b   Simon, M Celeste ^a,b,d  

^a Abramson Family Cancer Research Institute

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

c Myc; eIF4E binding protiens; Hypoxia; mRNA translation; Target of rapamycin; Tumor microenvironment

Indexed keywords

CYCLIN D1; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL XL; PROTEIN MAD2; SECURIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; INITIATION FACTOR 4E; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; EDEMA; GENE CONTROL; GENETIC CODE; HUMAN; HUMAN CELL; HYPOXIC CELL; IN VITRO STUDY; MITOSIS; NECROSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; TUMOR CELL; ANIMAL; ANOXIA; CELL STRUCTURE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANOXIA; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRUCTURES; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASMS; RHABDOMYOSARCOMA; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52149083002     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.9.6426     Document Type: Article

References (54)

1. Brown JM and Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:437-47.
2. Hockel M and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic and molecular aspects. J Natl Cancer Inst 2001; 93:266-76.
3. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15:551-78.
4. Koumenis C, et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol 2002; 22:7405-16.
5. Liu L, et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006; 21:521-31.
6. Kim JW, Tchernyshyov I, Semenza GL and Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3:177-85.
7. Papandreou I, Cairns RA, Fontana L, Lim AL and Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3:187-97.
8. Kapp LD and Lorsch JR. The molecular mechanics of eukaryotic translation. Annu Rev Biochem 2004; 73:657-704.
9. Richter JD and Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433:477-80.
10. Gingras AC, Raught B and Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68:913-63.
11. Liu L and Simon MC. Regulation of transcription and translation by hypoxia. Cancer Biol Ther 2004; 3:492-7.
12. Wouters BG, et al. Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev Biol 2005; 16:487-501.
13. Arsham AM, Howell JJ and Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278:29655-60.
14. Haghighat A, Mader S, Pause A and Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. Embo J 1995; 14:5701-9.
15. Pause A, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 1994; 371:762-7.
16. Gingras AC, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15:2852-64.
17. Brunn GJ, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277:99-101.
18. Burnett PE, Barrow RK, Cohen NA, Snyder SH and Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998; 95:1432-7.
19. Mothe-Satney I, Yang D, Fadden P, Haystead TA and Lawrence JC Jr. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol Cell Biol 2000; 20:3558-67.
20. Brugarolas J, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004; 18:2893-904.
21. Connolly E, Braunstein S, Formenti S and Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 2006; 26:3955-65.
22. Koritzinsky M, et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. Embo J 2006; 25:1114-25.
23. Koritzinsky M, et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol 2007.
24. Reiling JH and Hafen E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by downregulating S6K activity upstream of TSC in Drosophila. Genes Dev 2004; 18:2879-92.
25. Bernardi R, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006; 442:779-85.
26. Mamane Y, et al. eIF4E - from translation to transformation. Oncogene 2004; 23:3172-9.
27. Ruggero D, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10:484-6.
28. Wendel HG, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7.
29. Bjornsti MA and Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-48.
30. De Benedetti A and Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23:3189-99.
31. Mamane Y, et al. Epigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell Proliferation. PLoS ONE 2007; 2:242.
32. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M and Borden KL. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 2006; 175:415-26.
33. Lazaris-Karatzas A and Sonenberg N. The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol Cell Biol 1992; 12:1234-8.
34. Lazaris-Karatzas A, Montine KS and Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990; 345:544-7.
35. Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
36. Martin ME, et al. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000; 32:633-42.
37. Avdulov S, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004; 5:553-63.
38. Jacobson BA, et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 2006; 66:4256-62.
39. Li S, et al. Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol 2002; 22:2853-61.
40. Hernando E, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430:797-802.
41. Sotillo R, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007; 11:9-23.
42. Huang S, et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 2003; 11:1491-501.
43. Gardner LB, et al. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 2001; 276:7919-26.
44. Goda N, et al. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23:359-69.
45. Rosenwald IB, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995; 270:21176-80.
46. Clemens MJ and Bommer UA. Translational control: the cancer connection. Int J Biochem Cell Biol 1999; 31:1-23.
47. Fukumura D and Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101:937-49.
48. Kops GJ, Weaver BA and Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5:773-85.
49. Castellvi J, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107:1801-11.
50. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N and Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993; 13:7358-63.
51. Bi M, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. Embo J 2005; 24:3470-81.
52. Rodriguez-Perales S, et al. Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet 2004; 148:35-43.
53. Nelson DA, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 2004; 18:2095-107.
54. Easton JB and Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25:6436-46.